Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.

The euros and sense of stents: do we get value for money?

Annemans L.

J Cardiovasc Med (Hagerstown). 2011 Dec;12(12):878-82. doi: 10.2459/JCM.0b013e32834da507. Review. No abstract available.

PMID:
22025203
2.

Drug-eluting stents: more dollars than sense?

Garg S, Eisenberg MJ.

JACC Cardiovasc Interv. 2009 Dec;2(12):1188-9. doi: 10.1016/j.jcin.2009.11.001. No abstract available.

3.

Second-generation drug-eluting stents and the continuous need for rapidly available real-world data.

Mukherjee D, Moliterno DJ.

JACC Cardiovasc Interv. 2009 Dec;2(12):1236-9. doi: 10.1016/j.jcin.2009.10.010. No abstract available.

4.

Mid-term results and costs of coronary artery bypass vs drug-eluting stents for unprotected left main coronary artery disease.

Shimizu T, Ohno T, Ando J, Fujita H, Nagai R, Motomura N, Ono M, Kyo S, Takamoto S.

Circ J. 2010 Mar;74(3):449-55. Epub 2010 Jan 14.

5.

Economic evaluation of drug-eluting stents compared to bare metal stents using a large prospective study in Ontario.

Goeree R, Bowen JM, Blackhouse G, Lazzam C, Cohen E, Chiu M, Hopkins R, Tarride JE, Tu JV.

Int J Technol Assess Health Care. 2009 Apr;25(2):196-207. doi: 10.1017/S0266462309090254. Epub 2009 Mar 31.

PMID:
19331710
6.

Drug-eluting coronary-artery stents.

Stefanini GG, Holmes DR Jr.

N Engl J Med. 2013 Jan 17;368(3):254-65. doi: 10.1056/NEJMra1210816. Review. No abstract available.

7.

Cost-effectiveness of the real-world use of drug-eluting stents at 9-month follow-up: results from the Sicilian DES Registry.

Tamburino C, Barbagallo R, Capodanno D, di Matteo S, Colombo GL, Recchia M, Ciriminna S; Sicilian DES Registry Investigators.

J Cardiovasc Med (Hagerstown). 2009 Apr;10(4):322-9. doi: 10.2459/JCM.0b013e3283276ebb.

PMID:
19430343
8.

One-year clinical results and total costs of drug-eluting stents implantation in multivessel coronary artery disease.

Varani E, Balducelli M, Vecchi G, Aquilina M, Maresta A.

J Cardiovasc Med (Hagerstown). 2007 Aug;8(8):596-601.

PMID:
17667030
9.

Meeting report ESC forum on drug eluting stents, European Heart House, Nice, 27-28 September 2007.

Daemen J, Simoons ML, Wijns W, Bagust A, Bos G, Bowen JM, Braunwald E, Camenzind E, Chevaliers B, DiMario C, Fajadeto J, Gitt A, Guagliumi G, Hillege HL, James S, Jüni P, Kastrati A, Kloth S, Kristensen SD, Krucoff M, Legrand V, Pfisterer M, Rothman M, Serruys PW, Silber S, Steg PG, Tariah I, Wallentin L, Windecker SW, Aimonetti A, Allocco D, Berenger M, Boam A, Calle JP, Campo G, Carlier S, de Schepper J, Di Bisceglie G, Dobbels H, Farb A, Ghislain JC, Hellbardt S, ten Hoedt R, Isaia C, de Jong P, Lekehal M, LeNarz L, Mhullain FN, Nagai H, Patteet A, Paunovic D, Potgieter A, Purdy I, Raveau-Landon C, Ternstrom S, Van Wuytswinkel J, Waliszewski M; European Society of Cardiology.

EuroIntervention. 2009 Jan;4(4):427-36. No abstract available.

10.

Effectiveness is the key to cost-effectiveness.

Hlatky MA.

Circulation. 2013 Feb 19;127(7):764-5. doi: 10.1161/CIRCULATIONAHA.113.000639. No abstract available.

11.

Winners and losers from the cessation of the Cypher and NEVO stent programs.

Waksman R.

Cardiovasc Revasc Med. 2011 Sep-Oct;12(5):269-70. doi: 10.1016/j.carrev.2011.08.003. No abstract available.

PMID:
21907158
12.

Cost effectiveness of coronary revascularisation.

Birim O, Bogers AJ, Kappetein AP.

EuroIntervention. 2010 Feb;5(7):763-7. No abstract available.

PMID:
20142188
13.

Economic evaluation of fractional flow reserve-guided percutaneous coronary intervention in patients with multivessel disease.

Fearon WF, Bornschein B, Tonino PA, Gothe RM, Bruyne BD, Pijls NH, Siebert U; Fractional Flow Reserve Versus Angiography for Multivessel Evaluation (FAME) Study Investigators.

Circulation. 2010 Dec 14;122(24):2545-50. doi: 10.1161/CIRCULATIONAHA.109.925396. Epub 2010 Nov 29.

14.

Health economic outcomes of the SYNTAX trial.

Mack MJ.

Catheter Cardiovasc Interv. 2012 Feb 1;79(2):210. doi: 10.1002/ccd.24301. No abstract available.

PMID:
22271551
15.

Long-term clinical outcomes and cost-effectiveness analysis in multivessel percutaneous coronary interventions: comparison of drug-eluting stents, bare-metal stents and a mixed approach in patients at high and low risk of repeat revascularisation.

Varani E, Guastaroba P, Di Tanna GL, Saia F, Balducelli M, Campo G, Vignali L, Rossi R, Manari A, Piovaccari G, De Palma R, Marzocchi A.

EuroIntervention. 2010 Apr;5(8):953-61. doi: 10.4244/.

PMID:
20542781
16.

Cost-effectiveness of bypass surgery versus stenting in patients with multivessel coronary artery disease.

Yock CA, Boothroyd DB, Owens DK, Garber AM, Hlatky MA.

Am J Med. 2003 Oct 1;115(5):382-9.

PMID:
14553874
17.

Clinical outcomes and cost-utility after sirolimus-eluting versus bare metal stent implantation.

Zhao FH, Lü SZ, Li H, Ning SQ, Yuan F, Song XT, Jin ZN, Zhou Y, Chen X, Liu H, Tian R, Meng K, Li H, Han F.

Chin Med J (Engl). 2010 Oct;123(20):2797-802.

PMID:
21034585
18.

Economic evaluation of drug-eluting stents: a systematic literature review and model-based cost-utility analysis.

Kuukasjärvi P, Räsänen P, Malmivaara A, Aronen P, Sintonen H.

Int J Technol Assess Health Care. 2007 Fall;23(4):473-9. Review.

PMID:
17937836
19.

Drug-eluting stents for the treatment of coronary artery disease: NICE technology appraisal guidance.

Messori A, Trippoli S.

Heart. 2009 May;95(10):847. No abstract available.

PMID:
19401286
20.

How firms set prices for medical materials: a multi-country study.

Ide H, Mollahaliloglu S.

Health Policy. 2009 Sep;92(1):73-8. doi: 10.1016/j.healthpol.2009.03.003. Epub 2009 Apr 1.

PMID:
19342115

Supplemental Content

Support Center